A RANDOMIZED DOUBLE-BLIND PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM- BASED THERAPY AS FIRST LINE TREATMENT OF STAGE III OR IV NON-MUCINOUS EPITHELIAL OVARIAN CANCER

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Ovarian Cancer
  • Age: Between 18 - 100 Years
  • Gender: Female
  • Other Inclusion Criteria:
    1) Patients with a histologically confirmed diagnosis of nonmucinous epithelial ovarian cancer (serous, endometrial, clear cell, carcinosarcoma, and mixed pathologies) that is FIGO Stage III or IV. 2) Patients must provide a blood sample for molecular testing at screening. 3) Patient must provide a tumor tissue sample at screening for molecular testing.

You may not be eligible for this study if the following are true:

  • 1) Patients with mucinous, germ cell, transitional cell, or undifferentiated tumor. 2) Patients with low-grade / grade 1 epithelial ovarian cancer. 3) Stage III patients with no residual disease after primary surgery. 4) Patient who have not adequately recovered from prior major surgery.


If you are registered as a volunteer, please login to the dashboard to send referrals.